Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P15172
UPID:
MYOD1_HUMAN
Alternative names:
Class C basic helix-loop-helix protein 1; Myogenic factor 3
Alternative UPACC:
P15172; O75321
Background:
Myoblast determination protein 1, also known as Class C basic helix-loop-helix protein 1 or Myogenic factor 3, plays a pivotal role in muscle differentiation. It acts as a transcriptional activator, promoting the transcription of muscle-specific target genes. This protein, in concert with MYF5 and MYOG, occupies the muscle-specific gene promoter core region during myogenesis, driving fibroblasts to differentiate into myoblasts.
Therapeutic significance:
Linked to Congenital myopathy 17, a disorder characterized by muscle weakness and respiratory insufficiency, understanding the role of Myoblast determination protein 1 could open doors to potential therapeutic strategies. Its involvement in muscle differentiation pathways offers a promising target for therapeutic intervention.